HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The protective effect of Geniposide on diabetic cognitive impairment through BTK/TLR4/NF-κB pathway.

Abstract
The purpose of the present study was to elucidate the pharmacological effects of Geniposide (GEN) on high diet fed and streptozotocin (STZ)-caused diabetic cognitive impairment. The mice were fed with high fat diet (HFD) for 4 weeks and intraperitoneally injected with 60 mg/kg STZ for three times within 72 h. The mice with glucose level over 15 mmol/l were regarded as diabetic and selected for further studies. The animals were intragastrically treated with metformin or GEN once daily for 4 weeks. Afterwards, the animals were applied for Y maze, novel object recognition (NOR) test, step-through passive avoidance test, and Morris water maze (MWM) test. The blood glucose and body weight were examined. The SH-SY5Y cells were treated with GEN in the presence or absence of ibrutinib and stimulated with high-glucose culture medium. The tumor necrosis factor-a (TNF-α) and interleukin (IL)-6 in serum, hippocampus, and supernatant were measured using ELISA method. The protein expressions of Bruton's tyrosine kinase (BTK), Toll-like receptor 4 (TLR4), myeloid differentiating factor 88 (MyD88), nuclear factor kappa-B (NF-κB), p-NF-κB, brain-derived neurotrophic factor (BDNF), cAMP-response element binding protein (CREB), p-CREB, and glucagon-like peptide-1 receptor (GLP-1R) were detected by western blot analyses. As a result, the GEN treatment notably attenuated the body weight, blood glucose, and cognitive decline. GEN also inhibited the generations of inflammatory cytokines. Furthermore, the administrations of GEN ameliorated the alterations of BTK, TLR4, MyD88, NF-κB, and BDNF in HFD + STZ-induced mice. With the application of ibrutinib, the selective inhibitor of BTK, it was also found that BTK/TLR4/NF-κB pathway was associated with the GEN treatment in high glucose-induced SH-SY5Y cells. In summary, the results suggested that GEN exerted the protective effect on STZ-induced cognitive impairment possibly through the modulation of BTK/TLR4/NF-κB signaling.
AuthorsShengnan Liu, Menglin Zheng, Yixuan Li, Ling He, Tong Chen
JournalPsychopharmacology (Psychopharmacology (Berl)) Vol. 237 Issue 2 Pg. 465-477 (Feb 2020) ISSN: 1432-2072 [Electronic] Germany
PMID31811349 (Publication Type: Journal Article)
Chemical References
  • Blood Glucose
  • Iridoids
  • NF-kappa B
  • Tlr4 protein, mouse
  • Toll-Like Receptor 4
  • geniposide
  • Streptozocin
  • Agammaglobulinaemia Tyrosine Kinase
  • Btk protein, mouse
Topics
  • Agammaglobulinaemia Tyrosine Kinase (antagonists & inhibitors, metabolism)
  • Animals
  • Blood Glucose (drug effects, metabolism)
  • Cell Line, Tumor
  • Cognitive Dysfunction (drug therapy, metabolism)
  • Diabetes Mellitus (drug therapy, metabolism)
  • Dose-Response Relationship, Drug
  • Humans
  • Iridoids (pharmacology, therapeutic use)
  • Male
  • Mice
  • Mice, Inbred ICR
  • NF-kappa B (antagonists & inhibitors, metabolism)
  • Random Allocation
  • Signal Transduction (drug effects, physiology)
  • Streptozocin
  • Toll-Like Receptor 4 (antagonists & inhibitors, metabolism)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: